Protection with antibody to tumor necrosis factor differs with similarly lethal Escherichia coli versus Staphylococcus aureus pneumonia in rats

被引:25
作者
Karzai, W
Cui, XZ
Mehlhorn, B
Straube, E
Hartung, T
Gerstenberger, E
Banks, SM
Natanson, C
Reinhart, K
Eichacker, PQ
机构
[1] Univ Hosp, Dept Anesthesiol & Intens Care Med, Jena, Germany
[2] Univ Hosp, Dept Microbiol, Jena, Germany
关键词
D O I
10.1097/00000542-200307000-00016
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Differing factors may alter the effects of antibody to tumor necrosis factor (TNF) in infection and sepsis. The authors tested whether bacteria type or treatment route alters antibody to TNF in a rat model of bacterial pneumonia. Methods: Rats (n = 231) received similarly lethal doses of either intratracheal Escherichia coli or Staphylococcus aureus followed by treatment with either intratracheal or intraperitoneal antibody to TNF or control serum. Animals received antibiotics (cefotiam daily dose, 100 mg/kg) starting 4 h after inoculation and were studied for up to 96 h. Results: Compared with S. aureus, E coli increased serum TNF and interleukin-6 concentrations, lung lavage TNF concentrations, neutrophil counts, and alveolar-to-arterial oxygen gradients and decreased circulating nentrophils and lymphocytes (P greater than or equal to 0.05 for all). Compared with controls, with both bacteria, except for lung lavage TNF concentrations (which decreased with intratracheal but not with intraperitoneal antibody to TNF), treatment route did not alter the effects of antibody to TNF on any parameter (P = not significant for all). Antibody to TNF reduced mortality rates (relative risk of death +/- SEM) with both E. coli (-1.6 +/- 0.6; P = 0.006) and S. aureus (-0.5 +/- 0.04; P = 0.185), but these reductions were greater with E. coli than with S. aureus in a trend approaching statistical significance (P = 0.09). Compared with controls, similarly (P = not significant) with both bacteria, antibody to TNF decreased lung lavage and tissue bacteria concentrations (both P < 0.05) and serum TNF concentration (P < 0.09) and increased circulating neutrophils and lymphocytes (both P less than or equal to 0.01). Compared with S. aureus, with E. coli antibody to TNF decreased alveolar-to-arterial oxygen gradients (P = 0.04) and increased serum interleukin-6 concentrations (P = 0.003). Conclusion: Antibody to TNF improved host defense and survival rates with both lethal E. coli and S. aureus pneumonia, but protection was greater with E. coli, where TNF concentrations were higher than with S. aureus. The efficacy of antiinflammatory agents in sepsis may be altered by bacteria type.
引用
收藏
页码:81 / 89
页数:9
相关论文
共 62 条
  • [1] EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL
    ABRAHAM, E
    WUNDERINK, R
    SILVERMAN, H
    PERL, TM
    NASRAWAY, S
    LEVY, H
    BONE, R
    WENZEL, RP
    BALK, R
    ALLRED, R
    PENNINGTON, JE
    WHERRY, JC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12): : 934 - 941
  • [2] Abraham E, 1998, LANCET, V351, P929
  • [3] p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock - A randomized controlled multicenter trial
    Abraham, E
    Glauser, MP
    Butler, T
    Garbino, J
    Gelmont, D
    Laterre, PF
    Kudsk, K
    Bruining, HA
    Otto, C
    Tobin, E
    Zwingelstein, C
    Lesslauer, W
    Leighton, A
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (19): : 1531 - 1538
  • [4] Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients
    Abraham, E
    Laterre, PF
    Garbino, J
    Pingleton, S
    Butler, T
    Dugernier, T
    Margolis, B
    Kudsk, K
    Zimmerli, W
    Anderson, P
    Reynaert, M
    Lew, D
    Lesslauer, W
    Passe, S
    Cooper, P
    Burdeska, A
    Modi, M
    Leighton, A
    Salgo, M
    Van der Auwera, P
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (03) : 503 - 510
  • [5] *ANT DRUGS ADV COM, 2001, DROTR ALF ACT REC HU
  • [6] PROTECTION AGAINST ENDOTOXIC-SHOCK BY A TUMOR-NECROSIS-FACTOR RECEPTOR IMMUNOADHESIN
    ASHKENAZI, A
    MARSTERS, SA
    CAPON, DJ
    CHAMOW, SM
    FIGARI, IS
    PENNICA, D
    GOEDDEL, DV
    PALLADINO, MA
    SMITH, DH
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (23) : 10535 - 10539
  • [7] DIVERGENT EFFICACY OF ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA IN INTRAVASCULAR AND PERITONITIS MODELS OF SEPSIS
    BAGBY, GJ
    PLESSALA, KJ
    WILSON, LA
    THOMPSON, JJ
    NELSON, S
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (01) : 83 - 88
  • [8] Efficacy and safety of recombinant human activated protein C for severe sepsis.
    Bernard, GR
    Vincent, JL
    Laterre, P
    LaRosa, SP
    Dhainaut, JF
    Lopez-Rodriguez, A
    Steingrub, JS
    Garber, GE
    Helterbrand, JD
    Ely, EW
    Fisher, CJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) : 699 - 709
  • [9] PASSIVE-IMMUNIZATION AGAINST CACHECTIN TUMOR NECROSIS FACTOR PROTECTS MICE FROM LETHAL EFFECT OF ENDOTOXIN
    BEUTLER, B
    MILSARK, IW
    CERAMI, AC
    [J]. SCIENCE, 1985, 229 (4716) : 869 - 871
  • [10] Effect of a chimeric antibody to tumor necrosis factor-α on cytokine and physiologic responses in patients with severe sepsis -: A randomized, clinical trial
    Clark, MA
    Plank, LD
    Connolly, AB
    Streat, SJ
    Hill, AA
    Gupta, R
    Monk, DN
    Shenkin, A
    Hill, GL
    [J]. CRITICAL CARE MEDICINE, 1998, 26 (10) : 1650 - 1659